Bristol-Myers Squibb Co. (BMY)

Annual Data

Quarterly Data

Profitability ratios measure the company's ability to generate profitable sales from its resources (assets).

Bristol-Myers Squibb Co., profitability ratios

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Return on Sales
Gross profit margin	%	%	%	%	%
Operating profit margin	%	%	%	%	%
Net profit margin	%	%	%	%	%
Return on Investment
Return on equity (ROE)	%	%	%	%	%
Return on assets (ROA)	%	%	%	%	%

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

Ratio	Description	The company
Gross profit margin	Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures.	Bristol-Myers Squibb Co.'s gross profit margin deteriorated from 2015 to 2016 and from 2016 to 2017.
Operating profit margin	A profitability ratio calculated as operating income divided by revenue.	Bristol-Myers Squibb Co.'s operating profit margin improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017 not reaching 2015 level.
Net profit margin	An indicator of profitability, calculated as net income divided by revenue.	Bristol-Myers Squibb Co.'s net profit margin improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.
ROE	A profitability ratio calculated as net income divided by shareholders' equity.	Bristol-Myers Squibb Co.'s ROE improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.
ROA	A profitability ratio calculated as net income divided by total assets.	Bristol-Myers Squibb Co.'s ROA improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.

Bristol-Myers Squibb Co., gross profit margin calculation

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Selected Financial Data (USD $ in millions)
Gross margin
Revenues
Ratio
Gross profit margin¹	%	%	%	%	%
Benchmarks
Gross Profit Margin, Competitors
Abbott Laboratories	%	%	%	%	%
AbbVie Inc.	%	%	%	%	%
Allergan PLC	%	%	%	%	%
Amgen Inc.	%	%	%	%	%
Biogen Inc.	%	%	%	%	%
Celgene Corp.	%	%	%	%	%
Eli Lilly & Co.	%	%	%	%	%
Gilead Sciences Inc.	%	%	%	%	%
Johnson & Johnson	%	%	%	%	%
Merck & Co. Inc.	%	%	%	%	%
Pfizer Inc.	%	%	%	%	%
Regeneron Pharmaceuticals Inc.	%	%	%	%	%

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

2017 Calculations

¹ Gross profit margin = 100 × Gross margin ÷ Revenues
= 100 × hidden ÷ hidden = hidden %

Ratio	Description	The company
Gross profit margin	Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures.	Bristol-Myers Squibb Co.'s gross profit margin deteriorated from 2015 to 2016 and from 2016 to 2017.

Bristol-Myers Squibb Co., operating profit margin calculation, comparison to benchmarks

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Selected Financial Data (USD $ in millions)
Operating income
Revenues
Ratio
Operating profit margin¹	%	%	%	%	%
Benchmarks
Operating Profit Margin, Competitors
Abbott Laboratories	%	%	%	%	%
AbbVie Inc.	%	%	%	%	%
Allergan PLC	%	%	%	%	%
Amgen Inc.	%	%	%	%	%
Biogen Inc.	%	%	%	%	%
Celgene Corp.	%	%	%	%	%
Eli Lilly & Co.	%	%	%	%	%
Gilead Sciences Inc.	%	%	%	%	%
Johnson & Johnson	%	%	%	%	%
Merck & Co. Inc.	%	%	%	%	%
Pfizer Inc.	%	%	%	%	%
Regeneron Pharmaceuticals Inc.	%	%	%	%	%
Operating Profit Margin, Sector
Pharmaceuticals & Biotechnology	%	%	%	%	%
Operating Profit Margin, Industry
Health Care	%	%	%	%	%

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

2017 Calculations

¹ Operating profit margin = 100 × Operating income ÷ Revenues
= 100 × hidden ÷ hidden = hidden %

Ratio	Description	The company
Operating profit margin	A profitability ratio calculated as operating income divided by revenue.	Bristol-Myers Squibb Co.'s operating profit margin improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017 not reaching 2015 level.

Bristol-Myers Squibb Co., net profit margin calculation, comparison to benchmarks

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Selected Financial Data (USD $ in millions)
Net earnings attributable to BMS
Revenues
Ratio
Net profit margin¹	%	%	%	%	%
Benchmarks
Net Profit Margin, Competitors
Abbott Laboratories	%	%	%	%	%
AbbVie Inc.	%	%	%	%	%
Allergan PLC	%	%	%	%	%
Amgen Inc.	%	%	%	%	%
Biogen Inc.	%	%	%	%	%
Celgene Corp.	%	%	%	%	%
Eli Lilly & Co.	%	%	%	%	%
Gilead Sciences Inc.	%	%	%	%	%
Johnson & Johnson	%	%	%	%	%
Merck & Co. Inc.	%	%	%	%	%
Pfizer Inc.	%	%	%	%	%
Regeneron Pharmaceuticals Inc.	%	%	%	%	%
Net Profit Margin, Sector
Pharmaceuticals & Biotechnology	%	%	%	%	%
Net Profit Margin, Industry
Health Care	%	%	%	%	%

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

2017 Calculations

¹ Net profit margin = 100 × Net earnings attributable to BMS ÷ Revenues
= 100 × hidden ÷ hidden = hidden %

Ratio	Description	The company
Net profit margin	An indicator of profitability, calculated as net income divided by revenue.	Bristol-Myers Squibb Co.'s net profit margin improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.

Bristol-Myers Squibb Co., ROE calculation, comparison to benchmarks

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Selected Financial Data (USD $ in millions)
Net earnings attributable to BMS
Total Bristol-Myers Squibb Company shareholders' equity
Ratio
ROE¹	%	%	%	%	%
Benchmarks
ROE, Competitors
Abbott Laboratories	%	%	%	%	%
AbbVie Inc.	%	%	%	%	%
Allergan PLC	%	%	%	%	%
Amgen Inc.	%	%	%	%	%
Biogen Inc.	%	%	%	%	%
Celgene Corp.	%	%	%	%	%
Eli Lilly & Co.	%	%	%	%	%
Gilead Sciences Inc.	%	%	%	%	%
Johnson & Johnson	%	%	%	%	%
Merck & Co. Inc.	%	%	%	%	%
Pfizer Inc.	%	%	%	%	%
Regeneron Pharmaceuticals Inc.	%	%	%	%	%
ROE, Sector
Pharmaceuticals & Biotechnology	%	%	%	%	%
ROE, Industry
Health Care	%	%	%	%	%

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

2017 Calculations

¹ ROE = 100 × Net earnings attributable to BMS ÷ Total Bristol-Myers Squibb Company shareholders' equity
= 100 × hidden ÷ hidden = hidden %

Ratio	Description	The company
ROE	A profitability ratio calculated as net income divided by shareholders' equity.	Bristol-Myers Squibb Co.'s ROE improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.

Bristol-Myers Squibb Co., ROA calculation, comparison to benchmarks

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Selected Financial Data (USD $ in millions)
Net earnings attributable to BMS
Total assets
Ratio
ROA¹	%	%	%	%	%
Benchmarks
ROA, Competitors
Abbott Laboratories	%	%	%	%	%
AbbVie Inc.	%	%	%	%	%
Allergan PLC	%	%	%	%	%
Amgen Inc.	%	%	%	%	%
Biogen Inc.	%	%	%	%	%
Celgene Corp.	%	%	%	%	%
Eli Lilly & Co.	%	%	%	%	%
Gilead Sciences Inc.	%	%	%	%	%
Johnson & Johnson	%	%	%	%	%
Merck & Co. Inc.	%	%	%	%	%
Pfizer Inc.	%	%	%	%	%
Regeneron Pharmaceuticals Inc.	%	%	%	%	%
ROA, Sector
Pharmaceuticals & Biotechnology	%	%	%	%	%
ROA, Industry
Health Care	%	%	%	%	%

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

2017 Calculations

¹ ROA = 100 × Net earnings attributable to BMS ÷ Total assets
= 100 × hidden ÷ hidden = hidden %

Ratio	Description	The company
ROA	A profitability ratio calculated as net income divided by total assets.	Bristol-Myers Squibb Co.'s ROA improved from 2015 to 2016 but then deteriorated significantly from 2016 to 2017.

	Bristol-Myers Squibb Co.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Profitability Analysis